Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group.
Identifieur interne : 002888 ( Main/Exploration ); précédent : 002887; suivant : 002889Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group.
Auteurs : RBID : pubmed:16549819English descriptors
- KwdEn :
- MESH :
- chemical , blood : Calcitonin.
- chemical , therapeutic use : Antibodies, Monoclonal, Indium.
- methods : Radioimmunotherapy.
- mortality : Thyroid Neoplasms.
- radiotherapy : Thyroid Neoplasms.
- Humans, Pentetic Acid, Prognosis, Survival Analysis.
Abstract
No effective therapy is currently available for the management of patients with metastatic medullary thyroid carcinoma (MTC). The efficacy of pretargeted radioimmunotherapy (pRAIT) with bispecific monoclonal antibody (BsMAb) and a iodine-131 (131I) -labeled bivalent hapten is evaluated.
DOI: 10.1200/JCO.2005.04.4917
PubMed: 16549819
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group.</title><author><name sortKey="Chatal, Jean Francois" uniqKey="Chatal J">Jean-François Chatal</name><affiliation wicri:level="1"><nlm:affiliation>Department of Nuclear Medicine, Institut Régional du Cancer, Nantes, France. jfchatal@nantes.inserm.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Nuclear Medicine, Institut Régional du Cancer, Nantes</wicri:regionArea><placeName><region type="région">Pays de la Loire</region><settlement type="city">Nantes</settlement></placeName></affiliation></author><author><name sortKey="Campion, Loic" uniqKey="Campion L">Loïc Campion</name></author><author><name sortKey="Kraeber Bodere, Francoise" uniqKey="Kraeber Bodere F">Françoise Kraeber-Bodéré</name></author><author><name sortKey="Bardet, Stephane" uniqKey="Bardet S">Stephane Bardet</name></author><author><name sortKey="Vuillez, Jean Philippe" uniqKey="Vuillez J">Jean-Philippe Vuillez</name></author><author><name sortKey="Charbonnel, Bernard" uniqKey="Charbonnel B">Bernard Charbonnel</name></author><author><name sortKey="Rohmer, Vincent" uniqKey="Rohmer V">Vincent Rohmer</name></author><author><name sortKey="Chang, Chien Hsing" uniqKey="Chang C">Chien-Hsing Chang</name></author><author><name sortKey="Sharkey, Robert M" uniqKey="Sharkey R">Robert M Sharkey</name></author><author><name sortKey="Goldenberg, David M" uniqKey="Goldenberg D">David M Goldenberg</name></author><author><name sortKey="Barbet, Jacques" uniqKey="Barbet J">Jacques Barbet</name></author><author></author></titleStmt><publicationStmt><date when="2006">2006</date><idno type="doi">10.1200/JCO.2005.04.4917</idno><idno type="RBID">pubmed:16549819</idno><idno type="pmid">16549819</idno><idno type="wicri:Area/Main/Corpus">002C17</idno><idno type="wicri:Area/Main/Curation">002C17</idno><idno type="wicri:Area/Main/Exploration">002888</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Monoclonal (therapeutic use)</term><term>Calcitonin (blood)</term><term>Humans</term><term>Indium (therapeutic use)</term><term>Pentetic Acid</term><term>Prognosis</term><term>Radioimmunotherapy (methods)</term><term>Survival Analysis</term><term>Thyroid Neoplasms (mortality)</term><term>Thyroid Neoplasms (radiotherapy)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Calcitonin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Indium</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Radioimmunotherapy</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Thyroid Neoplasms</term></keywords><keywords scheme="MESH" qualifier="radiotherapy" xml:lang="en"><term>Thyroid Neoplasms</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Pentetic Acid</term><term>Prognosis</term><term>Survival Analysis</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">No effective therapy is currently available for the management of patients with metastatic medullary thyroid carcinoma (MTC). The efficacy of pretargeted radioimmunotherapy (pRAIT) with bispecific monoclonal antibody (BsMAb) and a iodine-131 (131I) -labeled bivalent hapten is evaluated.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">16549819</PMID><DateCreated><Year>2006</Year><Month>04</Month><Day>10</Day></DateCreated><DateCompleted><Year>2006</Year><Month>04</Month><Day>20</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1527-7755</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>11</Issue><PubDate><Year>2006</Year><Month>Apr</Month><Day>10</Day></PubDate></JournalIssue><Title>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</Title><ISOAbbreviation>J. Clin. Oncol.</ISOAbbreviation></Journal><ArticleTitle>Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group.</ArticleTitle><Pagination><MedlinePgn>1705-11</MedlinePgn></Pagination><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">No effective therapy is currently available for the management of patients with metastatic medullary thyroid carcinoma (MTC). The efficacy of pretargeted radioimmunotherapy (pRAIT) with bispecific monoclonal antibody (BsMAb) and a iodine-131 (131I) -labeled bivalent hapten is evaluated.</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">Twenty-nine patients with advanced, progressive MTC, as documented by short serum calcitonin doubling times (Ct DTs), received an anti-carcinoembryonic antigen (CEA)/anti-diethylenetriamine pentaacetic acid (DTPA) -indium BsMAb, followed 4 days later by a 131I-labeled bivalent hapten. Overall survival (OS) was compared with 39 contemporaneous untreated MTC patients with comparable prognostic indicators.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">OS was significantly longer in high-risk, treated patients (Ct DT < 2 years) than in high-risk, untreated patients (median OS, 110 v 61 months; P < .030). Forty-seven percent of patients, defined as biologic responders by a more than 100% increase in CtDT, experienced significantly longer survival than nonresponders (median OS, 159 v 109 months; P < .035) and untreated patients (median OS, 159 v 61 months; P < .010). Treated patients with bone/bone-marrow disease had a longer survival than patients without such involvement (10-year OS, 83% v 14%; P < .023). Toxicity was mainly hematologic and related to bone/bone-marrow tumor spread.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">pRAIT against CEA induced long-term disease stabilization and a significantly longer survival in high-risk patients with Ct DTs less than 2 years, compared with similarly high-risk, untreated patients. Ct DT and bone-marrow involvement appear to be prognostic indicators in MTC patients who undergo pRAIT.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chatal</LastName><ForeName>Jean-François</ForeName><Initials>JF</Initials><Affiliation>Department of Nuclear Medicine, Institut Régional du Cancer, Nantes, France. jfchatal@nantes.inserm.fr</Affiliation></Author><Author ValidYN="Y"><LastName>Campion</LastName><ForeName>Loïc</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Kraeber-Bodéré</LastName><ForeName>Françoise</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Bardet</LastName><ForeName>Stephane</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Vuillez</LastName><ForeName>Jean-Philippe</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Charbonnel</LastName><ForeName>Bernard</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Rohmer</LastName><ForeName>Vincent</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Chien-Hsing</ForeName><Initials>CH</Initials></Author><Author ValidYN="Y"><LastName>Sharkey</LastName><ForeName>Robert M</ForeName><Initials>RM</Initials></Author><Author ValidYN="Y"><LastName>Goldenberg</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Barbet</LastName><ForeName>Jacques</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><CollectiveName>French Endocrine Tumor Group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType>Clinical Trial</PublicationType><PublicationType>Journal Article</PublicationType><PublicationType>Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>03</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Oncol</MedlineTA><NlmUniqueID>8309333</NlmUniqueID><ISSNLinking>0732-183X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>045A6V3VFX</RegistryNumber><NameOfSubstance>Indium</NameOfSubstance></Chemical><Chemical><RegistryNumber>7A314HQM0I</RegistryNumber><NameOfSubstance>Pentetic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-12-9</RegistryNumber><NameOfSubstance>Calcitonin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Clin Oncol. 2006 Apr 10;24(11):1653-5</RefSource><PMID Version="1">16549818</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>J Clin Oncol. 2006 Jul 10;24(20):e37; author reply e38</RefSource><PMID Version="1">16829644</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Calcitonin</DescriptorName><QualifierName MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Indium</DescriptorName><QualifierName MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Pentetic Acid</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Radioimmunotherapy</DescriptorName><QualifierName MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Thyroid Neoplasms</DescriptorName><QualifierName MajorTopicYN="N">mortality</QualifierName><QualifierName MajorTopicYN="Y">radiotherapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="aheadofprint"><Year>2006</Year><Month>3</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>3</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>4</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>3</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pii">JCO.2005.04.4917</ArticleId><ArticleId IdType="doi">10.1200/JCO.2005.04.4917</ArticleId><ArticleId IdType="pubmed">16549819</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002888 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002888 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:16549819
|texte= Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:16549819" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a IndiumV2
| This area was generated with Dilib version V0.5.76. |  |